Description
Indication & Scope
AiRuiJing® is a prescription EZH2 inhibitor indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) who have received at least one prior systemic therapy.
- Mechanism: Zeprumetostat selectively inhibits enhancer of zeste homolog 2 (EZH2), reducing H3K27 trimethylation and restoring tumor suppressor gene expression to inhibit lymphoma cell proliferation and induce apoptosis.
- Drug class: EZH2 inhibitor.
- Clinical use: Treatment of adults with relapsed or refractory peripheral T-cell lymphoma after at least one prior systemic therapy.
| Generic Name | Zeprumetostat Tablets |
| Brand Name | AiRuiJing® |
| Ingredient | Zeprumetostat |
| Dosage Form | Tablet |
| Package | 50 mg × 98 tablets/bottle |
| Conditions Treated | Relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) |
| Taboos | Hypersensitivity to zeprumetostat or any component of the product; pregnancy |
| Place of origin | China |
| Prescription type | Prescription Drug (Rx) |
| Storage Conditions | Store below 25°C in a dry place, protected from moisture and light. |
| Manufacturer | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250057 |
| Date of Revision | 2025 |
| Shelf Life | Refer to the approved package labeling. |
How to use ?
Recommended Dose: The recommended dose is 350 mg orally twice daily (seven 50 mg tablets per dose), approximately 12 hours apart, with or without food, until disease progression or unacceptable toxicity.
Time: Take the tablets twice daily at approximately 12-hour intervals. Tablets should be swallowed whole and should not be crushed, chewed, or split.
Instructions for use: Administer orally with or without food. Continue treatment until disease progression or unacceptable toxicity. Dose interruption or reduction to 250 mg twice daily may be required for severe hematologic or non-hematologic adverse reactions. Regular monitoring of complete blood counts and liver function is recommended during treatment.
Interaction: Avoid concomitant use with strong CYP3A inhibitors or strong CYP3A inducers, as they may significantly alter zeprumetostat exposure. If co-administration with a moderate CYP3A inhibitor is unavoidable, dose adjustment should be considered.
Side effects: Common adverse reactions include thrombocytopenia, neutropenia, anemia, nausea, fatigue, elevated liver enzymes, hypokalemia, rash, pulmonary infection, diarrhea, decreased appetite, peripheral edema, and insomnia. Hematologic toxicities are the most common Grade ≥3 adverse reactions and require routine monitoring.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is AiRuiJing® (Zeprumetostat) used for?
It is indicated for adults with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) after at least one prior systemic therapy.
How is AiRuiJing® administered?
It is taken orally at 350 mg twice daily, with or without food.
What is the mechanism of action?
Zeprumetostat is a selective EZH2 inhibitor that suppresses lymphoma cell growth by inhibiting histone methylation.
What are the most common side effects?
Common adverse reactions include thrombocytopenia, neutropenia, anemia, nausea, fatigue, elevated liver enzymes, rash, and pulmonary infection.
AiRuiJing® | Zeprumetostat | PTCL | DengYueRX
INN: Zeprumetostat
Indications: Relapsed or refractory peripheral T-cell lymphoma
Dosage Form: Tablet
Strength: 50 mg/Tablet
